Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA)

Multidisciplinary strategies have transformed the management of advanced ovarian cancer. We aimed to evaluate the effectiveness of paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) following surgical cytoreduction for ovarian peritoneal metastases in a randomized phase III trial conduc...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Pedro Villarejo Campos, Susana Sánchez García, Mariano Amo-Salas, Esther García Santos, Carlos López de la Manzanara, Ana Alberca, David Padilla-Valverde, Francisco Javier Redondo Calvo, Jesús Martín
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2024-01-01
Serie:	Current Oncology
Soggetti:	advanced or recurrent ovarian cancer HIPEC paclitaxel cytoreduction peritoneal metastases peritoneal surface disease severity score
Accesso online:	https://www.mdpi.com/1718-7729/31/2/48
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!